NCT04153760View on ClinicalTrials.gov

Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

September 5, 2023

Study Completion Date

September 5, 2023

Conditions
Venous ThromboembolismPostpartum PeriodAspirin
Interventions
DRUG

Aspirin 81 mg

Aspirin 81 mg p.o. daily

DRUG

Placebo

Placebo p.o. daily

Trial Locations (7)

1105

The Amsterdam Medical Centre, Amsterdam

42270

Centre Hospitalier Universitaire de Saint-Etienne, Saint-Étienne-de-Montluc

T2N 2T9

Foothills Medical Centre, Calgary

V6H 3N1

British Columbia Women's Hospital & Health Centre, Vancouver

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

M5G 1Z5

Mount Sinai Hospital, Toronto

D01 P5W9

Rotunda Hospital, Dublin

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

NETWORK

lead

University of Calgary

OTHER

NCT04153760 - Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity | Biotech Hunter | Biotech Hunter